Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,901 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed-Platinum-Radiation in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: Results of a Phase I Trial.
Biswas T, Dowlati A, Kunos CA, Pink JJ, Oleinick NL, Malik S, Fu P, Cao S, Bruno DS, Bajor DL, Patel M, Gerson SL, Machtay M. Biswas T, et al. Among authors: fu p. Clin Cancer Res. 2022 Feb 15;28(4):646-652. doi: 10.1158/1078-0432.CCR-21-2025. Clin Cancer Res. 2022. PMID: 34740922 Free PMC article. Clinical Trial.
High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM. Wadhwa PD, et al. Among authors: fu p. Biol Blood Marrow Transplant. 2005 Jan;11(1):13-22. doi: 10.1016/j.bbmt.2004.09.003. Biol Blood Marrow Transplant. 2005. PMID: 15625540 Free article. Clinical Trial.
Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM, Simic A, Laughlin MJ, Gerson SL, Koç ON. van Heeckeren WJ, et al. Among authors: fu p. Br J Haematol. 2006 Jan;132(1):42-55. doi: 10.1111/j.1365-2141.2005.05827.x. Br J Haematol. 2006. PMID: 16371019 Free article. Clinical Trial.
O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
Batts ED, Maisel C, Kane D, Liu L, Fu P, O'Brien T, Remick S, Bahlis N, Gerson SL. Batts ED, et al. Among authors: fu p. Cancer Chemother Pharmacol. 2007 Aug;60(3):415-21. doi: 10.1007/s00280-007-0442-7. Epub 2007 Mar 13. Cancer Chemother Pharmacol. 2007. PMID: 17354015 Clinical Trial.
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, Silverman P, Robertson K, Ziats NP, Wasman JK, Abdul-Karim FW, Jesberger JA, Duerk J, Hartman P, Hanks S, Lewin J, Dowlati A, McCrae K, Ivy P, Remick SC. Overmoyer B, et al. Among authors: fu p. Clin Cancer Res. 2007 Oct 1;13(19):5862-8. doi: 10.1158/1078-0432.CCR-07-0688. Clin Cancer Res. 2007. PMID: 17908980 Clinical Trial.
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Gibbons J, Egorin MJ, Ramanathan RK, Fu P, Mulkerin DL, Shibata S, Takimoto CH, Mani S, LoRusso PA, Grem JL, Pavlick A, Lenz HJ, Flick SM, Reynolds S, Lagattuta TF, Parise RA, Wang Y, Murgo AJ, Ivy SP, Remick SC; National Cancer Institute Organ Dysfunction Working Group. Gibbons J, et al. Among authors: fu p. J Clin Oncol. 2008 Feb 1;26(4):570-6. doi: 10.1200/JCO.2007.13.3819. J Clin Oncol. 2008. PMID: 18235116 Clinical Trial.
2,901 results